OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143

BACKGROUND: Despite available treatment options for patients (pts) with recurrent glioblastoma (GBM), < 5% of pts survive 5 years beyond initial diagnosis, and no single-agent therapy has demonstrated a survival benefit in the second-line setting, including bevacizumab (bev), which is approved fo...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Reardon, D. A., Omuro, A., Brandes, A. A., Rieger, J., Wick, A., Sepulveda, J., Phuphanich, S., de Souza, P., Ahluwalia, M. S., Lim, M., Vlahovic, G., Sampson, J.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2017
Assuntos:
ORAL PRESENTATIONS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5463583/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.071
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares